Trial · NCT00858364
Results by group46
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 46
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | Placebo | 9.260 | 95% Confidence Interval 8.250 to 10.020 | months | |
| Overall Survival (OS) | Darbepoetin Alfa | 9.460 | 95% Confidence Interval 8.900 to 10.120 | months | |
| Progression-free Survival (PFS) | Placebo | 4.340 | 95% Confidence Interval 4.170 to 4.700 | months | |
| Progression-free Survival (PFS) | Darbepoetin Alfa | 4.800 | 95% Confidence Interval 4.370 to 5.320 | months | |
| Percentage of Participants With a Red Blood Cell Transfusion or Hemoglobin ≤ 8.0 g/dL From Week 5 to End of the Efficacy Treatment Period | Placebo | 29.2 | percentage of participants | ||
| Percentage of Participants With a Red Blood Cell Transfusion or Hemoglobin ≤ 8.0 g/dL From Week 5 to End of the Efficacy Treatment Period | Darbepoetin Alfa | 22.5 | percentage of participants | ||
| Number of Participants With Adverse Events of Special Interest | Placebo | Any adverse events of interest | 157 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Darbepoetin Alfa | Any adverse events of interest | 369 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Placebo | Antibody-mediated pure red cell aplasia | 20 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Darbepoetin Alfa | Antibody-mediated pure red cell aplasia | 51 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Placebo | Cardiac failure | 7 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Darbepoetin Alfa | Cardiac failure | 12 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Placebo | Central nervous system vascular disorders | 8 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Darbepoetin Alfa | Central nervous system vascular disorders | 25 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Placebo | Convulsions | 8 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Darbepoetin Alfa | Convulsions | 9 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Placebo | Embolic and thrombotic events | 34 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Darbepoetin Alfa | Embolic and thrombotic events | 89 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Placebo | Embolic and thrombotic events, arterial | 6 | Participants | |
| Number of Participants With Adverse Events of Special Interest | Darbepoetin Alfa | Embolic and thrombotic events, arterial | 19 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00858364/results